JWCA
ACAD icon

J.W. Cole Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

J.W. Cole Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$428K Sell
16,906
-3,726
-18% -$82K 0.01% 1094
2026
Q1 		$459K Hold
20,632
– – 0.02% 520
2025
Q4 		$551K Buy
20,632
+501
+2% +$12K 0.01% 853
2025
Q3 		$430K Buy
20,131
+150
+0.8% +$3.55K 0.01% 1055
2025
Q2 		$431K Sell
19,981
-3,045
-13% -$56.6K 0.01% 970
2025
Q1 		$382K Buy
23,026
+5,406
+31% +$98.2K 0.01% 861
2024
Q4 		$323K Hold
17,620
– – 0.01% 755
2024
Q3 		$271K Hold
17,620
– – 0.01% 809
2024
Q2 		$286K Hold
17,620
– – 0.01% 718
2024
Q1 		$326K Hold
17,620
– – 0.02% 664
2023
Q4 		$552K Hold
17,620
– – 0.03% 458
2023
Q3 		$367K Sell
17,620
-265
-1% -$7.2K 0.03% 503
2023
Q2 		$428K Hold
17,885
– – 0.03% 464
2023
Q1 		$337K Hold
17,885
– – 0.02% 564
2022
Q4 		$285K Hold
17,885
– – 0.02% 578
2022
Q3 		$293K Hold
17,885
– – 0.02% 543
2022
Q2 		$252K Sell
17,885
-25
-0.1% -$467 0.02% 599
2022
Q1 		$434K Hold
17,910
– – 0.03% 497
2021
Q4 		$418K Hold
17,910
– – 0.03% 532
2021
Q3 		$297K Hold
17,910
– – 0.02% 361
2021
Q2 		$437K Buy
17,910
+25
+0.1% +$564 0.03% 468
2021
Q1 		$461K Sell
17,885
-544
-3% -$23.9K 0.04% 403
2020
Q4 		$985K Sell
18,429
-775
-4% -$38.5K 0.1% 225
2020
Q3 		$792K Buy
19,204
+1,284
+7% +$55.4K 0.06% 305
2020
Q2 		$869K Buy
+17,920
New +$860K 0.13% 176
2020
Q1 		– Sell
-22,042
Closed -$943K – 103
2019
Q4 		$943K Buy
+22,042
New +$959K 0.12% 196

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

J.W. Cole Advisors's ACAD Position: Q2 2026 in Review

J.W. Cole Advisors reduced its Acadia Pharmaceuticals (ACAD) stake by 18% in Q2 2026, selling an estimated $82K and leaving 16,906 shares worth $428K. The position accounts for 0.01% of the portfolio, ranked #1094.

J.W. Cole Advisors first reported a position in ACAD in Q4 2019 and has held it in 26 quarters since. The position peaked at $985K in Q4 2020. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • J.W. Cole Advisors held 16,906 shares of Acadia Pharmaceuticals worth $428K as of Q2 2026.
  • J.W. Cole Advisors sold 3,726 Acadia Pharmaceuticals shares in Q2 2026, an estimated $82K.
  • Acadia Pharmaceuticals made up 0.01% of J.W. Cole Advisors's portfolio in Q2 2026, its #1094 holding.
  • J.W. Cole Advisors first reported a position in Acadia Pharmaceuticals in Q4 2019 and has held it in 26 quarters since.
  • J.W. Cole Advisors's Acadia Pharmaceuticals position peaked at $985K in Q4 2020.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on J.W. Cole Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.